Cantor Fitzgerald analyst Steve Seedhouse lowered the firm’s price target on Viking Therapeutics (VKTX) to $100 from $105 and keeps an Overweight rating on the shares. The firm expects subQ VK2735 Phase 3 readouts in obesity and in Type 2 diabetes in sequence in 2H27 and anticipates a superior product profile of VK2735 vs. tirzepatide, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Maintained at Buy as VK2735 Advances Through Phase 3, Price Target Reaffirmed at $102
- Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)
- Viking Therapeutics options imply 7.0% move in share price post-earnings
- VKTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Viking Therapeutics call volume above normal and directionally bullish